Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Fineline Cube Jul 1, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Deals

Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO

Fineline Cube Aug 19, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...

Company Drug

CSPC Pharmaceutical’s Mitoxantrone Liposome Approved for NMOSD Clinical Study

Fineline Cube Aug 19, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its mitoxantrone hydrochloride liposome has received...

Company Deals

Jemincare Licenses Oral Androgen Receptor Degrader to Roche’s Genentech

Fineline Cube Aug 18, 2022

China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech....

Company Drug R&D

Spinraza’s NRDL Inclusion Boosts SMA Patient Treatment in China

Fineline Cube Aug 18, 2022

The Meier Advocacy & Support Center for Spinal Muscular Atrophy (SMA) and the Shenzhen Research...

Policy / Regulatory

CDE Releases Draft Guidelines for RWE-Backed Drug Registration Applications

Fineline Cube Aug 18, 2022

The Center for Drug Evaluation (CDE) has released a notification regarding the “Real-World Evidence (RWE)-backed...

Drug

ICT’s GCC19CART Enters US Phase I Study for Colorectal Cancer

Fineline Cube Aug 18, 2022

Sino-US firm Innovative Cellular Therapeutics (ICT) announced the involvement of the first subject in a...

Drug

BRL Medicine’s BRL-101 Receives Clinical Trial Approval for Beta-Thalassemia

Fineline Cube Aug 18, 2022

Shanghai-based BRL Medicine Inc. has announced that it has received clinical trial approval from the...

Company Legal / IP

GenScript Biotech Sues Former CSO Fan Xiaohu for Trade Secret Infringement

Fineline Cube Aug 18, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has sued its former...

Company Drug

Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy

Fineline Cube Aug 18, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Digital Hospital

Baidu Health’s Precision Matching Engine Powers Public Hospitals

Fineline Cube Aug 18, 2022

China Internet giant Baidu’s one-stop health management platform Baidu Health has updated the status of...

Company

WuXi Biologics’ Revenues Surge 63.5% in H1 2022 on Strong CRDMO Growth

Fineline Cube Aug 18, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKEX: 2269) published its unaudited...

Company Deals

MingMed Biotech’s Hong Kong IPO Signals Push for First-in-Class Drugs

Fineline Cube Aug 18, 2022

Guangzhou-based MingMed Biotech has officially made an initial public offering (IPO) to the Hong Kong...

Company Drug

Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing

Fineline Cube Aug 18, 2022

China-based Junshi Biosciiences (HKG: 1877, SHA: 688180) has announced that another market approval filing for...

Company Deals

Applied Protein Technology Raises Hundreds of Millions in Series B Funding

Fineline Cube Aug 17, 2022

Shanghai-based Applied Protein Technology (APT Bio), a biotech company focused on mass spectrometry multi-omics precision...

Company Deals Drug

SciClone Licenses Menarini’s Vaborem to Tackle Drug-Resistant Infections in China

Fineline Cube Aug 17, 2022

SciClone Pharmaceuticals Inc (Nasdaq: SCLN), a China-based company since going private in 2017, announced a...

Company Drug

Zelgen Biopharmaceuticals’ ZGGS18 Receives NMPA Approval for Solid Tumor Treatment

Fineline Cube Aug 17, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Company Deals

Fortune Care Raises Hundreds of Millions in Series B for Elderly Care Expansion

Fineline Cube Aug 17, 2022

Fushoukang (Shanghai) Family Services Co., Ltd, also known as Fortune Care, a Shanghai-based smart elderly...

Medical Device

Bio-Heart’s BIOHEART-II Study Meets Primary Endpoint for Bioresorbable Scaffolds

Fineline Cube Aug 17, 2022

China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) announced that the BIOHEART-II study for...

Company

Sihuan Pharmaceutical Restructures with Dual Organization Model

Fineline Cube Aug 17, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced a structural reshuffling, setting up a...

Company Deals

Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China

Fineline Cube Aug 17, 2022

China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with...

Posts pagination

1 … 658 659 660 … 689

Recent updates

  • BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit
  • Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain
  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BeOne Medicines Reports 43% Reduction in Disease Progression with BRUKINSA-Rituximab Combo in Phase III MCL Study – Chemotherapy-Free Regimen Shows Significant PFS Benefit

Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.